Tomáš Hanke spends much of his time researching Virology, Immunology, Virus, Vaccinia and Epitope. His Virology research includes themes of CD8, Antigen, Immunogenicity, Cytotoxic T cell and CTL*. In his study, Viral load and HIV Antigens is strongly linked to AIDS Vaccines, which falls under the umbrella field of Immunology.
His research in Virus focuses on subjects like Immunity, which are connected to Immunization. His work on Orthopoxvirus is typically connected to Conserved sequence as part of general Vaccinia study, connecting several disciplines of science. His work in Epitope covers topics such as Immune system which are related to areas like Clinical trial and Hiv 1 vaccine.
His primary areas of investigation include Virology, Immunology, Virus, Epitope and Vaccination. The concepts of his Virology study are interwoven with issues in T cell, Immunogenicity, Vaccinia, Cytotoxic T cell and Immunogen. His study in AIDS Vaccines extends to Immunology with its themes.
His Virus study combines topics in areas such as Viral vector, Antibody and Heterologous. His Epitope research is multidisciplinary, incorporating perspectives in Simian and CD8. His research investigates the connection between Vaccination and topics such as HIV vaccine that intersect with issues in Cellular immunity.
His scientific interests lie mostly in Virology, Epitope, Vaccination, CD8 and Immune system. Tomáš Hanke does research in Virology, focusing on Virus specifically. His Virus research integrates issues from Vaccinia, Histocompatibility and Antigen presentation.
Tomáš Hanke interconnects Cytotoxic T cell, CTL* and HIV vaccine in the investigation of issues within Epitope. His Vaccination research is under the purview of Immunology. His work in CD8 addresses subjects such as T cell, which are connected to disciplines such as Modified vaccinia Ankara and Function.
The scientist’s investigation covers issues in Epitope, CD8, Vaccination, Immune system and Cytotoxic T cell. CD8 is frequently linked to T cell in his study. The ELISPOT research Tomáš Hanke does as part of his general T cell study is frequently linked to other disciplines of science, such as Context, therefore creating a link between diverse domains of science.
His study explores the link between Vaccination and topics such as Immunogenicity that cross with problems in Phases of clinical research and Viremia. His Immune system study necessitates a more in-depth grasp of Immunology. In Cytotoxic T cell, Tomáš Hanke works on issues like In vivo, which are connected to Virology, In vitro, Bivalent, AIDS Vaccines and Allele.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
Jörg Schneider;Sarah C. Gilbert;Tom J. Blanchard;Tomas Hanke.
Nature Medicine (1998)
Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen
Tomas Hanke;Rachel V. Samuel;Tom J. Blanchard;Veronica C. Neumann.
Journal of Virology (1999)
Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen
Todd M. Allen;Thorsten U. Vogel;Deborah H. Fuller;Bianca R. Mothé.
Journal of Immunology (2000)
HIV vaccines 1983-2003.
Andrew J McMichael;Tomas Hanke.
Nature Medicine (2003)
Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes
Nilu Goonetilleke;Stephen Moore;Len Dally;Nicola Winstone.
Journal of Virology (2006)
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Matilu Mwau;Inese Cebere;Julian Sutton;Priscilla Chikoti.
Journal of General Virology (2004)
Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
T. Hanke;T.J. Blanchard;J. Schneider;C.M. Hannan.
Vaccine (1998)
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
Sven Létourneau;Eung-Jun Im;Tumelo Mashishi;Choechoe Brereton.
PLOS ONE (2007)
Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
Tomas Hanke;Andrew J. McMichael.
Nature Medicine (2000)
DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice
Tomáš Hanke;Jörg Schneider;Sarah C. Gilbert;Adrian V.S. Hill.
Vaccine (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Oxford
University of Cambridge
University of Oxford
Los Alamos National Laboratory
RMIT University
University of Sheffield
University of Naples Federico II
University of St Andrews
International AIDS Vaccine Initiative
University of Oxford
Eindhoven University of Technology
University of Cagliari
Shandong University
National University of Singapore
Vrije Universiteit Brussel
National Oceanic and Atmospheric Administration
University of Pennsylvania
University of Notre Dame
University of Liverpool
Huazhong Agricultural University
Mahidol Oxford Tropical Medicine Research Unit
University of Tasmania
Saint Mary's University
University of York
Royal Hallamshire Hospital
University of Toronto